Found 579 Barrett's Esophagus trials
A listing of Barrett's Esophagus medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a multicenter, non-blinded, prospective observational cohort study of 1000 patients enrolled in an AlloSure testing registry, including 300 patients at centers with planned renal surveillance biopsies at 12 months post-transplantation. The other 700 patients will be from centers that do not perform protocol surveillance biopsies. This registry study …
Use of an HIV+ deceased donor could increase the risk of death, transplant-related or HIV-related complications; alternatively with effective antiretroviral treatment and careful HIV+ donor selection, these risks may be comparable to kidney transplant using an HIV-negative donor. We hypothesize that receiving a kidney transplant from an HIV+ donor will …
Adults 65 and older are more likely to have significant injuries from minor things like falls. They can have problems regaining strength due to sarcopenia (loss of muscle tissue as part of natural aging process). Nicotinamide riboside/pterstilbene (Basis) is commercially available nutraceutical. This randomized, double blind placebo controlled trial will …
The following protocol is a phase II study of the combination of the GITR agonist monoclonal antibody INCAGN01876, the anti-PD1 monoclonal antibody INCMGA00012, and SRS for recurrent GBM. We hypothesize that the proposed regimen will be safe and stimulate a robust anti-tumor immune response and result in improved tumor responses. …
SGM-101 is a fluorochrome-labeled anti-carcino-embryonic antigen (CEA) monoclonal antibody. What this means is that part of SGM-101 is a chemical that is attracted to and will attach to the cells of your cancer. Another part of SGM-101 is a chemical that will glow when infrared light is shined on it. …
The THINKER-NEXT research study is being done to determine whether it is safe to give a kidney transplant from a donor with hepatitis C to a patient without hepatitis C. The recipient will then be given a drug called Epclusa for 12 weeks to treat hepatitis C. Patients who are …
This is an interventional cohort study (n=10) that will involve external drainage of thoracic duct lymph in Surgical ICU patients with septic shock. The lymph drainage will continue for up to a maximum of 7 days and will be continued in those patients discharged from ICU back to the ward …
A multicenter, open label, randomized phase 2 study of I-131-1095 radiotherapy (less than or equal to 100 mCi/dose) every 8 weeks for up to 4 doses in combination with enzalutamide compared to enzalutamide alone in patients with progressive mCRPC. Patients must have documented progression on abiraterone and be indicated for …
Blood pressure treatment is important for all survivors of intracerebral hemorrhage (ICH). High blood pressure after ICH puts patients at high risk for future strokes and memory problems. Nearly all doctors agree that patients who have had a brain hemorrhage should be treated with blood pressure medications. But doctors are …
Venous thromboembolism (VTE) is a major complication occurring in hospitalized subjects. Although anticoagulants and mechanical prophylaxis are commonly used to prevent VTE it remains a leading cause of complications and death in the hospital population. The objective of this study is to evaluate device design with respect to initial clinical …
Please choose between Voice or SMS based delivery of verification code
or